BIOC:NSD-Biocept Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 3.79

Change

-0.07 (-1.81)%

Market Cap

USD 0.06B

Volume

0.20M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

+0.60 (+0.15%)

USD64.15B 78.50 53.56
IDXX IDEXX Laboratories Inc

+3.14 (+0.49%)

USD54.04B 75.72 54.89
DXCM DexCom Inc

-3.19 (-0.59%)

USD52.68B 102.00 115.62
ICLR ICON Public Limited Company

+1.53 (+0.56%)

USD21.92B 40.11 38.82
EXAS Exact Sciences Corporation

-3.13 (-3.16%)

USD17.02B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
NTRA Natera Inc

+0.62 (+0.56%)

USD10.39B N/A N/A
GH Guardant Health Inc

-2.16 (-2.13%)

USD10.29B N/A N/A
SYNH Syneos Health Inc

-0.60 (-0.68%)

USD9.08B 39.14 20.82
MEDP Medpace Holdings Inc

-1.26 (-0.67%)

USD6.70B 40.33 30.06

ETFs Containing BIOC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.64% 38% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.64% 38% F 26% F
Trailing 12 Months  
Capital Gain -19.02% 32% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.02% 32% F 16% F
Trailing 5 Years  
Capital Gain -98.64% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.64% 3% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -48.09% 2% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.09% 2% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.11% 63% D 35% F
Risk Adjusted Return -94.08% 2% F 1% F
Market Capitalization 0.06B 14% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.93 89% B+ 61% D-
Price / Cash Flow Ratio -2.87 49% F 60% D-
EV/EBITDA 430.20 6% F 3% F
Management Effectiveness  
Return on Equity -7.95% 65% D 46% F
Return on Invested Capital -88.66% 21% F 9% F
Return on Assets -2.89% 64% D 37% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.43 91% A- 71% C-
Short Percent 3.31% 67% D+ 46% F
Beta 0.68 76% C 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.